Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

5 evidence topics · 4 sources

In vitro affinity and potency compared with riliprubart
AssayClaseprubart (DNTH103)Riliprubart
Binding affinity to human active C1s, KD (KinExa)“9pM”“75pM”
Binding affinity to human active C1s, KD (SPR)“8pM”“35pM”
C4 cleavage by human active C1s, IC90 (nM)“0.47”“3.69”
Wieslab classical pathway assay in human serum, IC90 (μg/mL)“0.45”“5.4”
CH50 assay of RBC lysis in human serum, IC90 (μg/mL)“98”“668”
Liposome lysis in human serum, IC90 (μg/mL)“14.7”“39.8”